Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Stanford University
Boehringer Ingelheim
Eli Lilly and Company
Fred Hutchinson Cancer Center
Tomsk National Research Medical Center of the Russian Academy of Sciences
Kivu Bioscience Inc.
Alterome Therapeutics, Inc.
Ankyra Therapeutics, Inc
Daiichi Sankyo
ViroMissile, Inc.
Eli Lilly and Company
Pfizer
Astellas Pharma Inc
IntoCell, Inc
Pfizer
Pfizer
Tizona Therapeutics, Inc
InSilico Medicine Hong Kong Limited
ALX Oncology Inc.
Clasp Therapeutics, Inc.
Genentech, Inc.
Eli Lilly and Company
NiKang Therapeutics, Inc.
Eli Lilly and Company
USWM, LLC (dba US WorldMeds)
Werewolf Therapeutics, Inc.
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Prelude Therapeutics
Royal Marsden NHS Foundation Trust
Kyowa Kirin Co., Ltd.
Eli Lilly and Company
National Cancer Institute (NCI)
IDEAYA Biosciences
Plexium, Inc.
GlaxoSmithKline
Sairopa B.V.
Adaptimmune
Abramson Cancer Center at Penn Medicine
Tesaro, Inc.
National Cancer Institute (NCI)
University of California, San Diego
Incyte Corporation
Hummingbird Bioscience
Turning Point Therapeutics, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
NiKang Therapeutics, Inc.